SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001753926-21-000740
Filing Date
2021-11-29
Accepted
2021-11-26 17:49:29
Documents
7
Period of Report
2021-11-26

Document Format Files

Seq Description Document Type Size
1 6-K g082474_6k.htm 6-K 14043
2 EXHIBIT 99.1 g082474_ex99-1.htm EX-99.1 317700
3 EXHIBIT 99.2 g082474_ex99-2.htm EX-99.2 195386
4 EXHIBIT 99.3 g082474_ex99-3.htm EX-99.3 10085
5 EXHIBIT 99.4 g082474_ex99-4.htm EX-99.4 10077
6 GRAPHIC img001_v1.jpg GRAPHIC 11200
7 GRAPHIC img002_v1.jpg GRAPHIC 5214
  Complete submission text file 0001753926-21-000740.txt   571168
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 211452352
SIC: 2834 Pharmaceutical Preparations